• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cebranopadol: A First-in-Class Nociceptin Receptor Agonist for Managing Chronic Pain.

作者信息

Nair Abhijit S, Mantha Shyam Prasad, Pulipaka Sai Kaushik, Rayani Basanth Kumar

机构信息

Department of Anaesthesiology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, India.

出版信息

Indian J Palliat Care. 2020 Jan-Mar;26(1):147-148. doi: 10.4103/IJPC.IJPC_117_19. Epub 2020 Jan 28.

DOI:10.4103/IJPC.IJPC_117_19
PMID:32132804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7017681/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42f7/7017681/fecb1bbea452/IJPC-26-147-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42f7/7017681/fecb1bbea452/IJPC-26-147-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42f7/7017681/fecb1bbea452/IJPC-26-147-g001.jpg

相似文献

1
Cebranopadol: A First-in-Class Nociceptin Receptor Agonist for Managing Chronic Pain.塞布瑞诺帕多：一种用于治疗慢性疼痛的新型孤啡肽受体激动剂。
Indian J Palliat Care. 2020 Jan-Mar;26(1):147-148. doi: 10.4103/IJPC.IJPC_117_19. Epub 2020 Jan 28.
2
Nociceptin/orphanin FQ opioid peptide (NOP) receptor and µ-opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain.孤啡肽/强啡肽 FQ 阿片肽（NOP）受体和 μ 阿片肽（MOP）受体都有助于塞来昔布在关节炎疼痛大鼠模型中的抗敏效果。
Eur J Pharmacol. 2018 Aug 5;832:90-95. doi: 10.1016/j.ejphar.2018.05.005. Epub 2018 May 9.
3
Antihyperalgesic, Antiallodynic, and Antinociceptive Effects of Cebranopadol, a Novel Potent Nociceptin/Orphanin FQ and Opioid Receptor Agonist, after Peripheral and Central Administration in Rodent Models of Neuropathic Pain.新型强效痛敏肽/孤啡肽FQ与阿片受体激动剂塞布瑞诺帕在神经性疼痛啮齿动物模型中外周和中枢给药后的抗痛觉过敏、抗异常性疼痛和镇痛作用
Pain Pract. 2017 Nov;17(8):1032-1041. doi: 10.1111/papr.12558. Epub 2017 Feb 25.
4
Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.塞布若啡：一种新型强效阿片类药物孤啡肽/强啡肽 FQ 肽和阿片受体激动剂。
J Pharmacol Exp Ther. 2014 Jun;349(3):535-48. doi: 10.1124/jpet.114.213694. Epub 2014 Apr 8.
5
Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors.塞布诺帕多，一种混合阿片类激动剂，通过孤啡肽阿片受体和μ阿片受体减少可卡因自我给药。
Front Psychiatry. 2017 Nov 13;8:234. doi: 10.3389/fpsyt.2017.00234. eCollection 2017.
6
Cebranopadol: A Novel, First-in-Class, Strong Analgesic: Results from a Randomized Phase IIa Clinical Trial in Postoperative Acute Pain.塞来昔布钠：一种新型的、首创的、强效的镇痛药：在术后急性疼痛的随机 IIa 期临床试验中的结果。
Pain Physician. 2018 May;21(3):E193-E206.
7
Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic.新型首创类镇痛药塞来昔布的临床药代动力学特征。
Clin Pharmacokinet. 2018 Jan;57(1):31-50. doi: 10.1007/s40262-017-0545-1.
8
Inhibition of experimental visceral pain in rodents by cebranopadol.塞布瑞诺帕多对啮齿动物实验性内脏痛的抑制作用
Behav Pharmacol. 2019 Jun;30(4):320-326. doi: 10.1097/FBP.0000000000000420.
9
Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial.癌症相关慢性疼痛：新型镇痛药物候选药物塞来昔布在一项随机、双盲、非劣效性试验中的研究。
Eur J Pain. 2019 Mar;23(3):577-588. doi: 10.1002/ejp.1331. Epub 2019 Jan 9.
10
Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study.非依赖型阿片类药物娱乐使用者中塞布瑞诺帕朵滥用潜力的评估：一项1期随机对照研究。
J Clin Psychopharmacol. 2019 Jan/Feb;39(1):46-56. doi: 10.1097/JCP.0000000000000995.

引用本文的文献

1
Multimechanistic Single-Entity Combinations for Chronic Pain Control: A Narrative Review.用于慢性疼痛控制的多机制单一实体组合：一项叙述性综述。
Cureus. 2022 Jun 16;14(6):e26000. doi: 10.7759/cureus.26000. eCollection 2022 Jun.

本文引用的文献

1
Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors.塞布瑞诺帕多：一种通过NOP和阿片受体起作用的新型一流强效镇痛药。
Handb Exp Pharmacol. 2019;254:367-398. doi: 10.1007/164_2019_206.
2
Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial.癌症相关慢性疼痛：新型镇痛药物候选药物塞来昔布在一项随机、双盲、非劣效性试验中的研究。
Eur J Pain. 2019 Mar;23(3):577-588. doi: 10.1002/ejp.1331. Epub 2019 Jan 9.
3
Cebranopadol: A Novel, First-in-Class, Strong Analgesic: Results from a Randomized Phase IIa Clinical Trial in Postoperative Acute Pain.
塞来昔布钠：一种新型的、首创的、强效的镇痛药：在术后急性疼痛的随机 IIa 期临床试验中的结果。
Pain Physician. 2018 May;21(3):E193-E206.
4
Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial.塞来昔布，一种新型首创类镇痛药候选药物：在一项随机临床试验中慢性腰痛患者的初步临床经验。
Pain. 2017 Sep;158(9):1813-1824. doi: 10.1097/j.pain.0000000000000986.
5
Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic.新型首创类镇痛药塞来昔布的临床药代动力学特征。
Clin Pharmacokinet. 2018 Jan;57(1):31-50. doi: 10.1007/s40262-017-0545-1.
6
Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.塞布若啡：一种新型强效阿片类药物孤啡肽/强啡肽 FQ 肽和阿片受体激动剂。
J Pharmacol Exp Ther. 2014 Jun;349(3):535-48. doi: 10.1124/jpet.114.213694. Epub 2014 Apr 8.